Celldex Therapeutics, Inc. (CLDX) Stock Forecast Oct. 13, 2026
Analysis updated on Oct. 13, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Celldex Therapeutics, Inc. (CLDX) stock forecast summary
Our AI ranks Celldex Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Celldex Therapeutics, Inc. is a mid-cap company with a market capitalization of $2.22B. It ranks number 4 by market capitalization among the 15 In Vitro & In Vivo Diagnostic Substances issuers in our coverage with a current forecast. Its Net Margin of -191432.5% is the lowest of the 11 peers that report one.
A per-ticker accuracy statistic for CLDX is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, CLDX included.
Follow CLDX freeCLDX price chart and AI forecast
How CLDX ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Celldex Therapeutics, Inc. (CLDX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the In Vitro & In Vivo Diagnostic Substances peers listed below that report each metric.
Valuation & Market
| Metric | CLDX | Rank |
|---|---|---|
| Market Cap | $2.22B | 4/15 |
| P/B Ratio | 3.10x | 4/11 |
| EPS | $-5.17 | – |
| Book Value/Share | $9.10 | – |
| Revenue/Share | $0.00 | – |
| FCF/Share | $-3.08 | – |
Profitability & Margins
| Metric | CLDX | Rank |
|---|---|---|
| ROE | -42.1% | 7/11 |
| ROA | -38.4% | 8/13 |
| ROIC | -45.2% | 8/11 |
| Operating Margin | -207534.4% | 14/14 |
| Net Margin | -191432.5% | 11/11 |
| EBT Margin | -189311.5% | 14/14 |
Financial Health
| Metric | CLDX | Rank |
|---|---|---|
| Current Ratio | 11.82x | 2/15 |
| D/E Ratio | 0.09x | 11/12 |
| Financial Leverage | 1.09x | 11/12 |
| Interest Coverage | -260.2x | 11/14 |
| Working Capital | $664M | 2/15 |
Cash Flow
| Metric | CLDX | Rank |
|---|---|---|
| Operating Cash Flow | -$236M | 15/16 |
| Free Cash Flow | -$242M | 8/10 |
| Capital Spending | -$7M | 7/10 |
| FCF/Sales | -154207.0% | 10/10 |
| CapEx/Sales | 4165.0% | 1/10 |
Operational Efficiency
| Metric | CLDX | Rank |
|---|---|---|
| Asset Turnover | 0.00x | 11/12 |
| Fixed Assets Turnover | 0.0x | 11/12 |
Income Statement
| Metric | CLDX | Rank |
|---|---|---|
| Total Revenue | $0.00M | 11/12 |
| Operating Income | -$325M | 13/15 |
| Net Income | -$300M | 11/13 |
| R&D Expense | $279M | 2/16 |
Dividend & Shareholder Information
| Metric | CLDX | Rank |
|---|---|---|
| Shares Outstanding | 79M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $725M | 92.7% of assets |
| Cash & Short-term Investments | $47M | 6.1% of assets |
| Total Liabilities | $68M | 8.7% of assets |
| Short-term Debt | $47M | 6.0% of assets |
CLDX quarterly financials and insider trading
Celldex Therapeutics, Inc. (CLDX) industry peers
Companies classified under the same SEC industry code as Celldex Therapeutics, Inc. (In Vitro & In Vivo Diagnostic Substances): 17 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| CLDX Celldex Therapeutics, Inc. | ▲ | $2.22B |
| IDXX Idexx Laboratories Inc /De | ▼ | $40.99B |
| LNTH Lantheus Holdings, Inc. | ▼ | $6.53B |
| NEOG Neogen Corp | ▲ | $2.56B |
| NTLA Intellia Therapeutics, Inc. | ▲ | $1.67B |
| QDEL Quidelortho Corp | ▶ | $909M |
| ACHV Achieve Life Sciences, Inc. | ▶ | $720M |
| TKNO Alpha Teknova, Inc. | ▲ | $467M |
| MYGN Myriad Genetics Inc | ▲ | $390M |
| IMDX Insight Molecular Diagnostics Inc. | ▲ | $98M |
| ICCC Immucell Corp /De/ | ▲ | $87M |
| AWHL Aspira Women's Health Inc. | ▲ | $12M |
| BMRA Biomerica Inc | ▲ | $8M |
| CDIO Cardio Diagnostics Holdings, Inc. | ▶ | $5M |
| VNRX Volitionrx Ltd | ▼ | $3M |
| QCLS Q/C Technologies, Inc. | ▼ | N/A |
| TRIB Trinity Biotech Plc | ▼ | N/A |
Where CLDX sits on the market map
Celldex Therapeutics, Inc. (CLDX) stock news
Loading...
Celldex Therapeutics, Inc. (CLDX) stock forecast FAQ
What is the Celldex Therapeutics, Inc. (CLDX) stock forecast?
Our AI ranks Celldex Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Celldex Therapeutics, Inc. stock predictions?
A per-ticker accuracy statistic for CLDX is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Celldex Therapeutics, Inc. forecasts updated?
Celldex Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
Which companies are Celldex Therapeutics, Inc.'s industry peers?
17 issuers in our coverage, CLDX included, share the SEC industry code In Vitro & In Vivo Diagnostic Substances. The largest are: Idexx Laboratories Inc /De (IDXX), Lantheus Holdings, Inc. (LNTH), Neogen Corp (NEOG), Intellia Therapeutics, Inc. (NTLA), Quidelortho Corp (QDEL), Achieve Life Sciences, Inc. (ACHV).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.